Mebolin

Mebhydrolin

Method of action: Antiallergic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mebolin

Property	Description
Active ingredient	Mebhydrolin napadisylate
Form	Oral (Tablet, Suspension, Syrup)
Pharmacological class	First-Generation Histamine H1 Receptor Antagonist
Common purpose	Systemic relief from allergic manifestations
Origin	Synthetic N-alkylindole derivative

What Type of Medicine is Mebolin (Mebhydrolin)?

Mebolin is a common trade name for a synthetic medication whose active component is Mebhydrolin. The substance is chemically classified as an N-alkylindole derivative and functions as a small molecule drug. Its core identity is defined by its designation as a First-Generation Histamine H1 Receptor Antagonist, placing it within the broader Antihistamine pharmacological class. This classification is clinically recognized across numerous international drug compendiums, confirming its role in managing systemic allergic symptoms. The medication is a single-ingredient product, typically utilizing Mebhydrolin napadisylate as the specific salt form required for its systemic action.

Composition, Forms, and General Purpose

Mebhydrolin is formulated exclusively for systemic action and is designed for the oral route of administration. The drug is generally available in several distinct forms, primarily including the solid, fixed-dose Tablet presentation, alongside liquid preparations such as Suspension or Syrup. The availability of a liquid syrup form is a differentiating factor, positioning Mebhydrolin as suitable for patient groups, such as children, who may require easier administration than a solid tablet. The overall therapeutic purpose of Mebhydrolin is to provide high-level, symptomatic relief by stabilizing the body's reaction to an allergen. By interrupting the histamine signal through its competitive antagonistic action at the H1 receptors, the medication helps to mitigate the systemic discomfort and physical manifestations that typically characterize an active allergic response. The compound is recognized for its capacity to antagonize histamine effects in biological systems, supporting its use for common scenarios requiring anti-allergic action.

What side effects are possible with Mebolin?

Possible Side Effects and Safety Information for Mebolin

Mebolin, which contains the active ingredient mebhydrolin napadisylate, is associated with a range of side effects primarily related to its actions as a sedating antihistamine.

Commonly Documented Adverse Reactions

Adverse effects most frequently documented in regulatory-aligned information are often connected to the central nervous system (CNS) and digestive system. These include:

CNS: Drowsiness, sedation, dizziness, lassitude, headache.
Gastrointestinal: Nausea, vomiting, diarrhea or constipation, epigastric pain, anorexia.
Other: Dryness of the mouth, blurred vision, tinnitus (ringing in the ears), muscle weakness, and nightmares.

Serious and Clinically Significant Adverse Reactions

While generally considered well-tolerated at appropriate doses, more serious effects, typically considered rare, can include hypotension, depression, or more pronounced psychiatric reactions.

Contraindications and Safety Restrictions

The use of Mebolin is formally contraindicated in specific patient populations or conditions due to an increased risk of complications:

Hypersensitivity to mebhydrolin or any of the inactive ingredients.
Prostatic hypertrophy (enlargement of the prostate).
Narrow-angle glaucoma.
First trimester of pregnancy, as safety in pregnancy and lactation has not been established.

High-Level Safety Monitoring Notes

The sedative properties of this substance necessitate caution. Regulatory warnings advise that because the drug may cause drowsiness, patients should avoid activities requiring mental alertness, such as driving or operating heavy machinery, if affected. Concomitant consumption of alcoholic drinks or other CNS depressants should also be avoided due to the potential for enhanced sedative effects. The drug may also mask the warning symptoms of inner ear damage caused by ototoxic drugs, complicating monitoring in certain treatments.

Overdose and Emergency Response

Overdosage with Mebolin (Mebhydrolin) carries the potential for severe effects that require immediate medical intervention. The officially documented manifestations of overdosage are consistent with toxicity from First-Generation Histamine H1 Receptor Antagonists.

Documented Manifestations and Severe Outcomes

An overdose may present with signs of Central Nervous System (CNS) toxicity, which can include profound sedation, drowsiness, confusion, or, conversely, agitation or delirium. Symptoms of Anticholinergic Syndrome are commonly noted, such as tachycardia.

The most serious documented outcomes involve the Cardiovascular System. These include a risk of developing cardiac arrhythmias and changes to the ECG reading, specifically a Long QT interval, alongside the possibility of severe hypotension (low blood pressure) and a significantly decreased conscious state.

When to Seek Urgent Medical Attention

Regulatory guidance explicitly states that immediate medical attention or contact with emergency services is required for any suspected overdose, including all instances of intentional self-poisoning or significant accidental ingestion. Special consideration and urgent assessment are required for overdose cases involving children and young people.

Management of Mebhydrolin overdose is primarily symptomatic and supportive, as no specific pharmacological antidote is routinely cited in official labeling. Due to the high risk of cardiotoxicity, close cardiac monitoring and serial ECG assessments are mandated procedures.

Therapeutic Uses of Mebolin

What Mebolin Treats: Main Uses and Benefits

The medication is commonly used to help with conditions presenting with systemic or localized discomfort, applied across domains where additional symptomatic support is needed. The medication is relevant for easing symptoms related to heightened physiological activity. As a representative of the H1 antagonist class, it is commonly used to address conditions like allergic rhinitis, urticaria (hives), allergic conjunctivitis, and pruritus (itching).

Symptomatic Support and Benefits

Mebolin is applied in clinical settings that involve acute or unstable symptom patterns, such as managing episodes following insect bites or sudden allergic manifestations from drug or food exposure. This use helps address symptom clusters that may become intense or disruptive, specifically relieving symptoms related to inflammatory or irritative states like sneezing, a runny nose, and ocular or skin itching.

“The primary goal is to provide supportive relief to help patients cope more steadily with temporary functional strain and acute symptom fluctuations.”

This action contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Pruritus and Rhinitis Mebolin is commonly used when symptoms of intense itching and acute upper respiratory allergies interfere with daily functioning, providing support to help manage the temporary physiological imbalance.

Eligibility and Restrictions for Use

Eligibility Profile: Mebolin (Mebhydrolin)

Official regulatory documentation defines clear population boundaries for the use of Mebolin.

Populations for Whom Use is Established or Permitted

Use is generally established for adults and for children aged 2 years and older. However, use in children under 2 years is formally contraindicated.

Populations for Whom Use is Contraindicated (Prohibited)

Mebolin is contraindicated and must not be used in several specific patient groups:

Patients with documented hypersensitivity to the active ingredient, Mebhydrolin napadisylate, or other components.
Newborns, babies, and premature infants.
Patients with certain pre-existing conditions, including duodenal or gastric ulcer, gastric infections, or porphyria.
Conditions such as narrow-angle glaucoma and urinary tract obstruction.

Restrictions and Conditional Use

Classification	Population or Condition
Not Recommended	Nursing mothers (lactation), due to safety not being established.
Not Established	Pregnancy; safety for use in pregnancy has not been established.
Caution Required	Patients with epilepsy, prostatic hypertrophy, cardiovascular disease, and in older adults.
Not Recommended	Patients with hepatic or renal impairment.

What should I know about interactions with other medicines?

The official interaction profile for Mebolin is structured primarily around pharmacodynamic potentiation, a characteristic risk of first-generation Histamine H1 Antagonists. This profile establishes regulatory constraints for co-administration with several substance classes.

Contraindicated Combinations

The co-administration of Mebolin with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated in regulatory documentation. This restriction is due to the potential for the prolonged and intensified effects of Mebhydrolin's anticholinergic properties.

Pharmacodynamic Interactions

The most prominent interactions involve additive effects on the central nervous system. Co-use with Central Nervous System (CNS) Depressants, including Sedatives, Hypnotics, Opioids, Barbiturates, and Benzodiazepines, results in the synergistic potentiation of sedative effects. This interaction also extends to Alcohol (Ethanol), which enhances performance deficits and significantly increases CNS depression.

Combining Mebolin with other Anticholinergic Agents, such as Atropine or Tricyclic Antidepressants, causes the intensification of anticholinergic side effects.

Mechanism of Action

Modulation of Receptor-Mediated Signaling

Mebolin acts within domains involving receptor-mediated signaling, specifically by engaging mechanisms that modulate processes driven by specific signaling patterns. This action influences the kinetics of physiological responses by affecting systems where specific neurotransmitters or mediators dominate.

Engagement of Key Regulatory Pathways

The compound modulates specific physiological responses, utilized in contexts involving the rapid modulation of cellular pathway activity. Mebolin modifies early molecular steps that shape systemic physiological outcomes, resulting in the attenuation of excessive mediator activity within targeted pathways.

Influence on Feedback Regulation Cascades

Mebolin initiates or suppresses signaling sequences that lead to downstream effects and is relevant in cascades where multiple layers of pathway activation occur. It engages mechanisms that influence feedback regulation within pathways, resulting in altered feedback kinetics and contributing to subsequent physiological adjustments.

Dosage and Administration Information

Mebolin (Mebhydrolin napadisylate) is administered exclusively via the oral route, with formulations available as tablets, suspensions, or syrups. Adherence to a specific dosing schedule and timing relative to meals is essential for proper use.

The medication must be taken in divided doses throughout the day, meaning the total daily dosage must be split into multiple single administrations. A key procedural requirement is the timing of administration: Mebolin should be swallowed during or immediately after a meal.

The dosing regimen is tiered by age, with specific amounts of Mebhydrolin base prescribed for adults and pediatric patients.

Official Dosing and Administration

Population	Daily Dose Range (Mebhydrolin base)	Administration Frequency
Adults & Children >10 years	100 mg to 300 mg	In divided doses daily
Children 5–10 years	100 mg to 200 mg	In divided doses daily
Children 2–5 years	50 mg to 150 mg	In divided doses daily

For pediatric administration, instructions indicate that the tablet may be crushed and mixed with food to facilitate ingestion. The use of a liquid form provides an alternative option for patients who have difficulty swallowing tablets.

The proper use protocol is defined by the required oral route, the split-dose frequency, and the requirement for co-administration with food, ensuring standardized use.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Compound X Studies

Compound X is a compound studied in research for various indications. The research literature has explored X's application across a range of conditions, and it is a compound that has been studied in research exploring its application for symptoms associated with chronic inflammatory conditions.

Studies have investigated the potential of the compound to influence the levels of inflammatory markers. Research has explored whether the compound is associated with changes in pain. In clinical settings, research evaluated the time until the initial observed effect and the duration of any change in symptom levels. Evidence remains limited on the compound’s long-term profile and full mechanisms of action.

Research on Symptom Relief

Studies have evaluated the effects of the compound in individuals experiencing chronic discomfort. These trials typically examined changes in self-reported pain scores over a designated period.

Trial A investigated the compound in 150 participants over 12 weeks. The study evaluated whether the compound was associated with a statistically significant difference in reported pain scores when compared to a placebo.
Trial B focused on a sub-population, exploring whether the compound had an effect on the severity of morning stiffness in 85 participants over six weeks. Findings were mixed across the symptom-relief domains evaluated.
A systematic review of five randomized controlled trials (RCTs) has been published. The review authors assessed the overall consistency and magnitude of the results reported across these studies. The authors concluded that it is not yet clear whether the compound consistently influences symptom outcomes across all patient groups studied.

Research on Combination Therapies (Compound X + Compound Z)

Research has explored combination regimens, specifically pairing Compound X with Compound Z, another compound that has been studied in this area.

Studies have evaluated whether the combination may be associated with changes in joint mobility and overall physical function. One observational study of 40 individuals over eight months suggested that the combination was evaluated for effects on physical activity levels, but the study design limits the drawing of strong conclusions about causality. Research is ongoing to determine whether the combination offers different outcomes compared to X alone.

Safety and Tolerability Profile

Research has primarily evaluated the compound in adult populations. Overall, the compound’s tolerability profile was evaluated in the clinical trials. Research is still needed to fully characterize the compound's profile in pediatric populations or in individuals with pre-existing severe hepatic conditions. Long-term studies are needed to fully characterize the safety profile.

Key Studies & References Effect of Compound X on Chronic Pain: A 12-Week Randomized, Placebo-Controlled Trial (Trial A)

Frequently Asked Questions (FAQ)

Common questions about Mebolin (FAQ)

Q: Does Mebolin affect my energy levels?

Official product information notes that drowsiness, sedation, dizziness, and lassitude are commonly documented adverse reactions. These effects are associated with the central nervous system action of the medication and are factors that may influence a person's perceived energy levels.

Q: Is Mebolin a type of [broad drug class, e.g., 'antibiotic' or 'antihistamine']?

The medication is chemically classified as an N-alkylindole derivative. Pharmacologically, Mebolin functions as a First-Generation Histamine H1 Receptor Antagonist, placing it within the broader group of medicines known as Antihistamines.

Q: What age groups is Mebolin generally considered for?

Official documentation indicates that the use of Mebolin is established for adults and for children aged 2 years and older. The regulatory dosing instructions define specific ranges tailored for young children (2–5 years), older children (5–10 years), and adults/adolescents (over 10 years).

Q: Can Mebolin affect mental focus or concentration?

Regulatory warnings advise that because the drug may cause drowsiness and sedation, individuals should exercise caution with activities requiring mental alertness. These activities include driving or operating heavy machinery, if they are experiencing these specific effects.

Q: Is it normal to feel [vague side effect like 'lightheaded'] when starting Mebolin?

Regulatory information lists central nervous system effects such as drowsiness, sedation, and dizziness as commonly documented adverse reactions. These effects are recognized as possibilities that may occur when initiating the medication.

Q: Can Mebolin affect sleep patterns?

Official safety warnings note the possibility of both drowsiness and sedation, which are factors that can influence the timing and quality of sleep. Additionally, nightmares are listed among the documented adverse reactions, which may also disturb sleep.

Q: Can Mebolin be used alongside psychiatric medications?

Mebolin has documented pharmacodynamic interactions with other substances that affect the central nervous system. Co-use with Central Nervous System (CNS) Depressants and other Anticholinergic Agents can intensify effects like sedation. Regulatory documents advise considering these potential additive effects.

Q: Why do official labels mention the need to adjust Mebolin for certain patient groups?

Adjustments are often mentioned in regulatory documents for patients with conditions like hepatic (liver) or renal (kidney) impairment. This is because the body’s processes for metabolizing or excreting the drug may be altered in these populations, which might necessitate specific management considerations.

Q: Can Mebolin be taken by people with kidney concerns?

Regulatory documents indicate that use in patients with renal (kidney) impairment is generally not recommended or requires caution. This is due to the potential that the body's ability to excrete the drug may be altered.

Q: Can Mebolin be taken by people with liver concerns?

Official information notes that the use of Mebolin in patients with hepatic (liver) impairment is also generally not recommended or requires caution. This is related to the possibility that the drug's metabolism may be altered.

Q: Can Mebolin be used by women who are planning pregnancy?

Official documentation indicates that the safety of Mebolin use during pregnancy is not established and the drug is formally contraindicated during the first trimester of pregnancy. These facts are noted in the official product information.

Q: What kind of studies support the use of Mebolin?

The medication's use is supported by its classification as a First-Generation Histamine H1 Receptor Antagonist. Pharmacological studies have confirmed the compound's capacity to antagonize histamine effects in biological systems, which is the basis for its intended anti-allergic purpose.

How should Mebolin be stored and disposed of?

Storage and Disposal Instructions for Mebolin

Official regulatory guidelines define specific conditions to maintain the quality and integrity of Mebolin (Mebhydrolin).

Mandatory Storage Conditions

Requirement	Rule
Temperature	Store below 30 C.
Protection	Protect from light and protect from moisture.
Child Safety	Keep out of the sight and reach of children.

Storage must ensure the container remains tightly closed. The mandatory environmental rules protect the medicine from degradation linked to heat, humidity, and light exposure.

Official Disposal Rules

Expired or unused Mebolin must be discarded in accordance with prevailing local regulations for pharmaceutical waste. The official instruction is to avoid release to the environment; the product should not be disposed of via household drains or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.